RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:436174

Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome

medium confidenceDisorder

Also known as: CAGSSS

Publications

420

77.5th percentile

Trials

0

Interventional, condition-specific

Researchers

222

Distinct authors in sample

Gene link

IARS2

Strong

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare disease characterized by a highly variable phenotypic spectrum comprising delayed motor development, peripheral , cataract, short stature due to growth hormone deficiency, nystagmus, sensorineural hearing loss, facial features, and skeletal abnormalities consistent with spondyloepimetaphyseal . Hyperextensible joints, achalasia, and telangiectasia have also been described. Cognition is normal. Atrophy of the pituitary gland has been observed in brain imaging.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Strong — IARS2

  2. LiteraturePresent

    420 matched papers (327 in last 10 years) Source

  3. Phenotype characterisedPresent

    90 HPO annotations (e.g. Motor delay; Hip dislocation; Narrow mouth) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (IARS2).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

90

Associated phenotypes · MONDO:0014455

  • Motor delay
  • Hip dislocation
  • Narrow mouth
  • Prelingual sensorineural hearing impairment
  • Cataract

Showing 5 of 90 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

420

420 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

420 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

327 in the last 10 years · medium confidence · 77.5th percentile (publications denominator)

Phrase hits: 32 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

222

Distinct author names in 32 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Antonellis A3 papers · 2025

    Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, United States; Cellular and Molecular Biology Program, University of Michigan Medical School, Ann Arbor, MI, United States. Electronic address: antonell@umich.edu.

    Papers in Europe PMC
  2. 02
    Nishimura G3 papers · 2025

    Department of Radiology, Musashino-Yowakai Hospital, Tokyo, Japan.

    Papers in Europe PMC
  3. 03
    Cai C2 papers · 2024

    Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, People's Republic of China.

    Papers in Europe PMC
  4. 04
    Li D2 papers · 2024

    Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, People's Republic of China.

    Papers in Europe PMC
  5. 05
    Liu X2 papers · 2024

    Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, People's Republic of China.

    Papers in Europe PMC
  6. 06
    Sheng W2 papers · 2024

    Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, People's Republic of China.

    Papers in Europe PMC
  7. 07
    Shu J2 papers · 2024

    Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, People's Republic of China.

    Papers in Europe PMC
  8. 08
    Yi G2 papers · 2024

    Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, People's Republic of China.

    Papers in Europe PMC
  9. 09
    Zhou F2 papers · 2024

    Tianjin Children's Hospital (Tianjin University Children's Hospital), Tianjin, People's Republic of China.

    Papers in Europe PMC
  10. 10
    Abdygalyk B1 paper · 2025

    Department of Neurology, Kazakhstan's Medical University "KSPH", Almaty 050060, Kazakhstan.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

medium confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome" OR "CAGSSS") OR ("IARS2" OR "IARS2 syndrome" OR "IARS2-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome" OR "CAGSSS"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (420) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium

Ingested 2026-07-27T16:09:41.385Z